UNLOCKING THE POTENTIAL OF THE IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

The Latest News

March 31, 2021

Dr. Wei R. Chen Elected to the 2022 Class of the AIMBE College of Fellows

Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being...
Read More
March 28, 2022

SIO Annual Scientific Meeting, March 24 -28, 2022

Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 –...
Read More
March 11, 2022

2022 NYSE IPO Summit

Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from...
Read More